|Forum - Wall Street Pit
||Stock Due Diligence for All|
|From: SunTzu772 (Rep: 1149) reply to SunTzu772||Date: 06/10/2019 14:00|
|Forum: Wall Street Pit - Msg #2789541||Thread #674085452 (Rec: 2) |
|$10+ tgt..up to $800m milestone payments and royalties...mkt cap $7.8m lure in price action shorts and give it time this will be a major winner -|
"Total payments of Xynomic associated with the licensing agreement, including an upfront payment, regulatory milestone payments and potential royalties, will be up to $800 million."
Xynomic Pharma Acquires Global Exclusive Rights to Phase 2 Ready mTORC1/2 Inhibitor from Boehringer Ingelheim
------------------- "Opportunities multiply as they are seized" -- Sun Tzu circa 500 B.C. -------------------
| Reply to SunTzu772 - Msg #2789516 - 06/10/2019 12:35|
Re: 4.99 vol halt #2..$6 test halt #3..DD @ 2.41..320k float pharma lowest ever.
June 06, 2019 12:30 ET | Source: Xynomic Pharmaceuticals Holdings, Inc.
RALEIGH, N.C. and SHANGHAI, June 06, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, Nasdaq: XYN), a clinical stage US-China oncology drug development company, announced that Xynomic has dosed the first patient in a Phase 1/2 trial that combines abexinostat with ibrutinib in patients with relapsed/refractory mantle cell lymphoma (“r/r MCL”) or relapsed/refractory diffuse large B-cell lymphoma (“r/r DLBCL”) at Memorial Sloan Kettering Cancer Center (MSK). This trial will enroll approximately 40 patients to assess the safety and efficacy of the combination in patients with r/r MCL or r/r DLBCL. This trial will also explore the biologic predictors of response and resistance to dual B-cell receptor (BCR) and histone deacetylase (HDAC) inhibition. Janssen Biotech, Inc. is providing ibrutinib as part of the study, with Xynomic providing abexinostat and funding support for the trial being conducted at MSK.
Mantle cell lymphoma (MCL) has an annual incidence of approximately 6,500 in G7 countries, according to DR/Decision Resources, LLC. Ibrutinib has been approved by the United States Food and Drug Administration (FDA) for relapsed MCL and has response rates of 60-70% and median duration of response of 18 months. Abexinostat as a mono therapy has been shown to have response rate of 15.4% (7.7% complete response and 7.7% partial response) in r/r MCL patients. Researchers at MSK are testing whether abexinostat/ibrutinib combo could potentially improve response rates and duration of responses in r/r MCL patients, subject to the assessment upon the completion of the trial.
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin’s lymphoma (NHL) subtype according to the Leukemia & Lymphoma Society (LLS). Researchers at MSK have shown preclinical data demonstrating that dual targeting of Bruton’s tyrosine kinase (BTK) in the BCR pathway with ibrutinib and inhibition of MyD88-driven NF-kB activation with a HDAC inhibitor lead to synergistic anti-lymphoma activity in MyD88 mutated, ABC-subtype DLBCL both in vitro and in vivo.
Abexinostat is a novel HDAC inhibitor in global pivotal trials against NHL and renal cell carcinoma. Ibrutinib is a first-in-class BTK inhibitor jointly developed and commercialized as IMBRUVICA® by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company and has been approved for multiple hematological malignances and chronic graft-versus-host-disease (cGVHD).
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.